Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
97.01
-0.15 (-0.15%)
May 26, 2026, 12:45 PM EDT - Market open
Incyte Employees
Incyte had 2,844 employees as of December 31, 2025. The number of employees increased by 227 or 8.67% compared to the previous year.
Employees
2,844
Change (1Y)
227
Growth (1Y)
8.67%
Revenue / Employee
$1,885,028
Profits / Employee
$503,438
Market Cap
19.38B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,844 | 227 | 8.67% |
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Insmed | 1,664 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
INCY News
- 4 hours ago - Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 1 day ago - Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out - MarketBeat
- 4 days ago - Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound - TheFly
- 4 days ago - Incyte initiated with a Market Perform at Bernstein - TheFly
- 6 days ago - Inside Incyte's $120 Million AI For Drug Development Deal - Forbes
- 6 days ago - Incyte, Genesis Molecular AI announce expansion of collaboration - TheFly
- 6 days ago - Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery - Business Wire
- 7 days ago - Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts